Natural control of HIV infection in young women in South Africa: HPTN 068

References

• Okulicz JF, Lambotte O. Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS. 2011;6(3):163–168.
   PubMed Web of Science ®Google Scholar
• Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis. 2009;200(11):1714–1723.
   PubMed Web of Science ®Google Scholar
• Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197(4):563–571.
   PubMed Web of Science ®Google Scholar
• Taborda NA, Rugeles MT, Montoya CJ. Spontaneous control of HIV replication, but not HAART-induced viral suppression, is associated with lower activation of immune cells. J Acquir Immune Defic Syndr. 2014;66(4):365–369.
   PubMed Web of Science ®Google Scholar
• Miura T, Brumme ZL, Brockman MA, et al. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol. 2010;84(15):7581–7591.
   PubMed Web of Science ®Google Scholar
• Bello G, Velasco-de-Castro CA, Bongertz V, et al. Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1. J Med Virol. 2009;81(10):1681–1690.
   PubMed Web of Science ®Google Scholar
• Olson AD, Meyer L, Prins M, et al. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. PLoS One. 2014;9(1):e86719.
   PubMed Web of Science ®Google Scholar
• Crowell TA, Hatano H. Clinical outcomes and antiretroviral therapy in 'elite' controllers: a review of the literature. J Virus Erad. 2015;1(2):72–77.
   PubMed Web of Science ®Google Scholar
• Blankson JN. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res. 2010;85(1):295–302.
   PubMed Web of Science ®Google Scholar
• Theze J, Chakrabarti LA, Vingert B, Porichis F, Kaufmann DE. HIV controllers: a multifactorial phenotype of spontaneous viral suppression. Clin Immunol. 2011;141(1):15–30.
   PubMed Web of Science ®Google Scholar
• Yang OO, Cumberland WG, Escobar R, Liao D, Chew KW. Demographics and natural history of HIV-1-infected spontaneous controllers of viremia. AIDS. 2017;31(8):1091–1098.
   PubMed Web of Science ®Google Scholar
• Crowell TA, Gebo KA, Blankson JN, et al. Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J Infect Dis. 2015;211(11):1692–1702.
   PubMed Web of Science ®Google Scholar
• Mandalia S, Westrop SJ, Beck EJ, Nelson M, Gazzard BG, Imami N. Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010. PLoS One. 2012;7(2):e29844.
   PubMed Web of Science ®Google Scholar
• Marzinke MA, Clarke W, Wang L, et al. Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection. Clin Infect Dis. 2014;58(1):117–120.
   PubMed Web of Science ®Google Scholar
• Chen I, Clarke W, Ou SS, et al. Antiretroviral drug use in a cohort of HIV-uninfected women in the United States: HIV Prevention Trials Network 064. PLoS One. 2015;10(10):e0140074.
   PubMed Web of Science ®Google Scholar
• Pettifor A, MacPhail C, Selin A, et al. HPTN 068: A randomized control trial of a conditional cash transfer to reduce HIV infection in young women in South Africa-study design and baseline results. AIDS Behav. 2016;20(9):1863–1882.
   PubMed Web of Science ®Google Scholar
• Pettifor A, MacPhail C, Hughes JP, et al. The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial. Lancet Glob Health. 2016;4(12):e978–e988.
   PubMed Web of Science ®Google Scholar
• South African National Department of Health. Clinical guidelines for the managements of HIV & AIDS in adults and adolescents. 2010; http://www.who.int/hiv/pub/guidelines/south_africa_art.pdf. Accessed August 16, 2018.
   Google Scholar
• Marzinke MA, Breaud A, Parsons TL, et al. The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. Clin Chim Acta. 2014;433:157–168.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Clarke W, Marzinke MA, et al. Evaluation of a multidrug assay for monitoring adherence to a regimen for HIV preexposure prophylaxis in a clinical study, HIV Prevention Trials Network 073. Antimicrob Agents Chemother. 2017;61(7).
   Web of Science ®Google Scholar
• de Oliveira T, Deforche K, Cassol S, Rambaut A, Vandamme A-M. REGA HIV-1 subtyping tool. 2014; http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/. Accessed December 7, 2016.
   Google Scholar
• Groves KC, Bibby DF, Clark DA, et al. Disease progression in HIV-1-infected viremic controllers. J Acquir Immune Defic Syndr. 2012;61(4):407–416.
   PubMed Web of Science ®Google Scholar
• Ndhlovu ZM, Chibnik LB, Proudfoot J, et al. High-dimensional immunomonitoring models of HIV-1-specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control. Blood. 2013;121(5):801–811.
   PubMed Web of Science ®Google Scholar
• International HIV Controllers Study, Pereyra F, Jia X, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010;330(6010):1551–1557.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sivay MV, Hudelson SE, et al. Antiretroviral drug use and HIV drug resistance among young women in rural South Africa: HPTN 068. J Acquir Immune Defic Syndr. 2018;79:315–322.
   PubMed Web of Science ®Google Scholar
• Sivay MV, Hudelson SE, Wang J, et al. HIV-1 diversity among young women in rural South Africa: HPTN 068. Plos One. 2018;13(7):e0198999.
   PubMed Web of Science ®Google Scholar
• Kranzer K, Lawn SD, Johnson LF, Bekker LG, Wood R. Community viral load and CD4 count distribution among people living with HIV in a South African Township: implications for treatment as prevention. J Acquir Immune Defic Syndr. 2013;63(4):498–505.
   PubMed Web of Science ®Google Scholar
• Laeyendecker O, Redd AD, Lutalo T, et al. Frequency of long-term nonprogressors in HIV-1 seroconverters From Rakai Uganda. J Acquir Immune Defic Syndr. 2009;52(3):316–319.
   PubMed Web of Science ®Google Scholar
• Goujard C, Chaix ML, Lambotte O, et al. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis. 2009;49(6):982–986.
   PubMed Web of Science ®Google Scholar
• Chen I, Connor MB, Clarke W, et al. Antiretroviral drug use and HIV drug resistance among HIV-infected black men who have sex with men: HIV Prevention Trials Network 061. J Acquir Immune Defic Syndr. 2015;69(4):446–452.
   PubMed Web of Science ®Google Scholar
• Fogel JM, Zhang Y, Guo X, et al. Reliability of self-reported HIV status among African MSM screened for HPTN 075 Paper presented at: Conference on retroviruses and opportunistic infections; 4-7 March, 2018; Boston.
   Google Scholar
• Fogel JM, Wang L, Parsons TL, et al. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013;208(10):1624–1628.
   PubMed Web of Science ®Google Scholar
• Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197(1):126–133.
   PubMed Web of Science ®Google Scholar
• Walker BD, Yu XG. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol. 2013;13(7):487–498.
   PubMed Web of Science ®Google Scholar
• Harrison L, Castro H, Cane P, et al. The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS. 2010;24(12):1917–1922.
   PubMed Web of Science ®Google Scholar
• Lamine A, Caumont-Sarcos A, Chaix ML, et al. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS. 2007;21(8):1043–1045.
   PubMed Web of Science ®Google Scholar
• Blankson JN, Bailey JR, Thayil S, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol. 2007;81(5):2508–2518.
   PubMed Web of Science ®Google Scholar
• Martinez-Picado J, Martinez MA. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 2008;134(1-2):104–123.
   PubMed Web of Science ®Google Scholar
• Easterbrook PJ, Smith M, Mullen J, et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc. 2010;13:4.
   PubMed Web of Science ®Google Scholar
• Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis. 2008;197(5):707–713.
   PubMed Web of Science ®Google Scholar
• Venner CM, Nankya I, Kyeyune F, et al. Infecting HIV-1 subtype predicts disease progression in women of sub-Saharan Africa. EBioMedicine. 2016;13:305–314.
   PubMed Web of Science ®Google Scholar
• Kharsany AB, Buthelezi TJ, Frohlich JA, et al. HIV infection in high school students in rural South Africa: role of transmissions among students. AIDS Res Hum Retroviruses. 2014;30(10):956–965.
   PubMed Web of Science ®Google Scholar